Showing 81-90 of 4005 results for "".
Hidden in Plain Sight: A Modern Guide to Detecting and Managing Early Neurotrophic Keratitis
https://reachmd.com/live-events/hidden-in-plain-sight-a-modern-guide-to-detecting-and-managing-early-neurotrophic-keratitis/54616/Can you detect NK early and accurately? Join our experts for a Dinner Symposium to learn about the most effective diagnostic strategies and best practices in the management of NK.Location: OnlineDate: March 12, 2026; 06:30 PM - 07:30 PM ET- Women’s Health: Beyond the Annual Visit - CMEhttps://reachmd.com/cme/womens-health-education/
- From HFSA 2025: The Latest in Managing Patients With HFrEF - Programshttps://reachmd.com/programs/HFSA2025/
- DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF) - CMEhttps://reachmd.com/cme/ACC-2025-nsMRA-HF/
- Immuno-Oncology (IO) Updates - Programshttps://reachmd.com/programs/immuno-oncology-io-updates/Keep up-to-date on the latest management options for all cancer types, including: non-small cell lung cancer, head and neck, and more! This series provides an overview of efficacy and safety of strategies targeting the immune system, including the use of immune-modifying agents, and immune checkpoi…
- FCDC Action Center - Programshttps://reachmd.com/programs/fcdc-action-center/
Latest Clinical Trial Outcomes and Breakthroughs for FCS
https://reachmd.com/programs/cme/latest-clinical-trial-outcomes-and-breakthroughs-for-fcs/33223/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.FCS: Enhancing the Diagnosis
https://reachmd.com/programs/cme/fcs-enhancing-the-diagnosis/33220/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.The Road Ahead: What's on the Horizon for FCS and SHTG Management
https://reachmd.com/programs/cme/the-road-ahead-whats-on-the-horizon-for-fcs-and-shtg-management/33228/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.APOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
https://reachmd.com/programs/cme/apoc3-inhibition-new-frontiers-managing-patients-with-fcs-shtg/20307/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.